Cardio-Protective Effects of Sodium-Glucose Co-Transporter 2 Inhibitors: Focus on Heart Failure

Dimos       Karangelis; C.    David    Mazer; Dimitrios       Stakos; Aphrodite       Tzifa; Spiros       Loggos; Subodh       Verma; Fotios       Mitropoulos

doi:10.2174/1381612826666201103122813

Abstract

Background: Type 2 diabetes mellitus (DM) is associated with a considerable risk of cardiovascular and renal diseases, including heart failure. Sodium-glucose co-transporter 2 (SGLT2) inhibitors have demonstrated unprecedented cardiorenal protective effects in large-scale clinical trials of patients with or without diabetes and either established cardiovascular disease (CV) or multiple CV risk factors.

Objective: Herein we aim to focus on the role of SGLT2 inhibitors regarding the improvement in heart failure outcomes and the proposed mechanisms of action by which these drugs confer their beneficial effect.

Methods: PubMed, Embase, and Google Scholar databases were searched to identify eligible articles that are comprehensively summarized and discussed in this study.

Results: The most commonly discussed mechanisms of action are diuresis and natriuresis, reduction in preload, afterload, and ventricular mass, as well as stimulation of erythropoietin production and improved myocardial energetics. SGLT2 inhibitors improve outcomes in patients with established heart failure (HF) and reduce the risk of death and HF admissions in patients with established chronic HF with reduced ejection fraction (HFrEF), either with or without diabetes.

Conclusion: Potential key mechanisms that may explain the notable cardioprotective benefits of SGLT2 inhibitors have been outlined. These agents have recently received class Ia recommendation in specific groups of people with DM to lower the risk of hospitalization for HF and risk of death, while these benefits may also extend to people without diabetes. It remains to be seen whether they will also emerge as treatment approaches in the acute phase of CV episodes.

Keywords: SGLT2 inhibitors, heart failure, cardiovascular events, diabetes mellitus, cardioprotective effects, antidiabetics.

« Previous Next »

[1] 
Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract  2011; 94(3): 311-21.
[http://dx.doi.org/10.1016/j.diabres.2011.10.029] [PMID: 22079683] 
[2] 
Lotfy M, Adeghate J, Kalasz H, Singh J, Adeghate E. Chronic complications of diabetes mellitus: a mini review. Curr Diabetes Rev  2017; 13(1): 3-10.
[http://dx.doi.org/10.2174/1573399812666151016101622] [PMID: 26472574] 
[3] 
Lehrke M, Marx N. Diabetes mellitus and heart failure. Am J Cardiol  2017; 120(1S): S37-47.
[http://dx.doi.org/10.1016/j.amjcard.2017.05.014] [PMID: 28606342] 
[4] 
Cosentino F, Grant PJ, Aboyans V, et al. ESC Scientific Document Group. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J  2020; 41(2): 255-323.
[http://dx.doi.org/10.1093/eurheartj/ehz486] [PMID: 31497854] 
[5] 
Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med  1991; 325(5): 293-302.
[http://dx.doi.org/10.1056/NEJM199108013250501] [PMID: 2057034] 
[6] 
Fitchett DH, Udell JA, Inzucchi SE. Heart failure outcomes in clinical trials of glucose-lowering agents in patients with diabetes. Eur J Heart Fail  2017; 19(1): 43-53.
[http://dx.doi.org/10.1002/ejhf.633] [PMID: 27653447] 
[7] 
Monami M, Dicembrini I, Mannucci E. Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis  2014; 24(7): 689-97.
[http://dx.doi.org/10.1016/j.numecd.2014.01.017] [PMID: 24793580] 
[8] 
Zinman B, Wanner C, Lachin JM, et al. EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med  2015; 373(22): 2117-28.
[http://dx.doi.org/10.1056/NEJMoa1504720] [PMID: 26378978] 
[9] 
Neal B, Perkovic V, Mahaffey KW, et al. CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med  2017; 377(7): 644-57.
[http://dx.doi.org/10.1056/NEJMoa1611925] [PMID: 28605608] 
[10] 
Wiviott SD, Raz I, Bonaca MP, et al. DECLARE–TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med  2019; 380(4): 347-57.
[http://dx.doi.org/10.1056/NEJMoa1812389] [PMID: 30415602] 
[11] 
Fitchett D, Zinman B, Wanner C, et al. EMPA-REG OUTCOME® trial investigators. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial. Eur Heart J  2016; 37(19): 1526-34.
[http://dx.doi.org/10.1093/eurheartj/ehv728] [PMID: 26819227] 
[12] 
Inzucchi SE, Zinman B, Fitchett D, et al. How does empagliflozin reduce cardiovascular mortality? insights from a mediation analysis of the EMPA-REG OUTCOME trial. Diabetes Care  2018; 41(2): 356-63.
[http://dx.doi.org/10.2337/dc17-1096] [PMID: 29203583] 
[13] 
Verma L, Leiter A, Sharma Z, et al. How Early after Treatment Initiation Are the CV Benefits of Empagliflozin Apparent? A Post Hoc Analysis of EMPA-REG OUTCOME. Diabetes  2020; 69: 28.
[http://dx.doi.org/10.2337/db20-28-OR] 
[14] 
Swoboda PP, McDiarmid AK, Erhayiem B, et al. Diabetes mellitus, microalbuminuria, and subclinical cardiac disease: identification and monitoring of individuals at risk of heart failure. J Am Heart Assoc  2017; 6(7): e005539.
[http://dx.doi.org/10.1161/JAHA.117.005539] [PMID: 28716801] 
[15] 
Maack C, Lehrke M, Backs J, et al. Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association-European Society of Cardiology. Eur Heart J  2018; 39(48): 4243-54.
[http://dx.doi.org/10.1093/eurheartj/ehy596] [PMID: 30295797] 
[16] 
Mahaffey KW, Neal B, Perkovic V, et al. CANVAS Program Collaborative Group. Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS Program (Canagliflozin Cardiovascular Assessment Study). Circulation  2018; 137(4): 323-34.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.117.032038] [PMID: 29133604] 
[17] 
Fitchett D, Butler J, van de Borne P, et al. EMPA-REG OUTCOME® trial investigators. Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial. Eur Heart J  2018; 39(5): 363-70.
[http://dx.doi.org/10.1093/eurheartj/ehx511] [PMID: 29020355] 
[18] 
Rådholm K, Figtree G, Perkovic V, et al. Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program. Circulation  2018; 138(5): 458-68.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.118.034222] [PMID: 29526832] 
[19] 
McMurray JJV, Solomon SD, Inzucchi SE, et al. DAPA-HF Trial Committees and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med  2019; 381(21): 1995-2008.
[http://dx.doi.org/10.1056/NEJMoa1911303] [PMID: 31535829] 
[20] 
Nassif ME, Windsor SL, Tang F, et al. DEFINE-HF Investigators. Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction: the DEFINE-HF trial. Circulation  2019; 140(18): 1463-76.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.119.042929] [PMID: 31524498] 
[21] 
Fitchett D, Inzucchi SE, Cannon CP, et al. Empagliflozin reduced mortality and hospitalization for heart failure across the spectrum of cardiovascular risk in the EMPA-REG OUTCOME trial. Circulation  2019; 139(11): 1384-95.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.118.037778] [PMID: 30586757] 
[22] 
Damman K, Beusekamp JC, Boorsma EM, et al. Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF). Eur J Heart Fail  2020; 22(4): 713-22.
[http://dx.doi.org/10.1002/ejhf.1713] [PMID: 31912605] 
[23] 
A Study to Test the Effect of Empagliflozin in Patients Who Are in Hospital for Acute Heart Failure. EMPULSE trial ClinicalTrialsgov Identifier NCT04157751, 2020.
[24] 
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835- 004).  Available at: https://clinicaltrials.gov/ct2/show/NCT01986881
[25] 
Verma S, McMurray JJV, Cherney DZI. The metabolodiuretic promise of sodium-dependent glucose cotransporter 2 inhibition: the search for the sweet spot in heart failure. JAMA Cardiol  2017; 2(9): 939-40.
[http://dx.doi.org/10.1001/jamacardio.2017.1891] [PMID: 28636701] 
[26] 
Verma S, McMurray JJV. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia  2018; 61(10): 2108-17.
[http://dx.doi.org/10.1007/s00125-018-4670-7] [PMID: 30132036] 
[27] 
Hallow KM, Helmlinger G, Greasley PJ, McMurray JJV, Boulton DW. Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis. Diabetes Obes Metab  2018; 20(3): 479-87.
[http://dx.doi.org/10.1111/dom.13126] [PMID: 29024278] 
[28] 
Sano M, Goto S. Possible mechanism of hematocrit elevation by sodium glucose cotransporter 2 inhibitors and associated beneficial renal and cardiovascular effects. Circulation  2019; 139(17): 1985-7.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.118.038881] [PMID: 31009585] 
[29] 
Mazer CD, Hare GMT, Connelly PW, et al. Effect of Empagliflozin on Erythropoietin Levels, Iron Stores, and Red Blood Cell Morphology in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease. Circulation  2020; 141(8): 704-7.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.119.044235] [PMID: 31707794] 
[30] 
Verma S, Mazer CD, Yan AT, et al. Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial. Circulation  2019; 140(21): 1693-702.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.119.042375] [PMID: 31434508] 
[31] 
Ferrannini E, Mark M, Mayoux E. CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis. Diabetes Care  2016; 39(7): 1108-14.
[http://dx.doi.org/10.2337/dc16-0330] [PMID: 27289126] 
[32] 
Santos-Gallego CG, Requena-Ibanez JA, San Antonio R, et al. Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics. J Am Coll Cardiol  2019; 73(15): 1931-44.
[http://dx.doi.org/10.1016/j.jacc.2019.01.056] [PMID: 30999996] 
[33] 
Yurista SR, Silljé HHW, Oberdorf-Maass SU, et al. Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction. Eur J Heart Fail  2019; 21(7): 862-73.
[http://dx.doi.org/10.1002/ejhf.1473] [PMID: 31033127] 
[34] 
Gormsen LC, Svart M, Thomsen HH, et al. Ketone Body Infusion With 3-Hydroxybutyrate Reduces Myocardial Glucose Uptake and Increases Blood Flow in Humans: A Positron Emission Tomography Study. J Am Heart Assoc  2017; 6(3): e005066.
[http://dx.doi.org/10.1161/JAHA.116.005066] [PMID: 28242634] 
[35] 
Nielsen R, Møller N, Gormsen LC, et al. Cardiovascular Effects of Treatment With the Ketone Body 3-Hydroxybutyrate in Chronic Heart Failure Patients. Circulation  2019; 139(18): 2129-41.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.118.036459] [PMID: 30884964] 
[36] 
Kidokoro K, Cherney DZI. Evaluation of Glomerular Hemodynamic Function by Empagliflozin in Diabetic Mice Using In Vivo Imaging. Circulation  2019; 140(4): 303-15.
[37] 
Griffin M, Rao VS, Ivey-Miranda J, et al. Empagliflozin in Heart Failure: Diuretic and Cardiorenal Effects. Circulation  2020; 142(11): 1028-39.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.120.045691] [PMID: 32410463] 
[38] 
Ye Y, Jia X, Bajaj M, Birnbaum Y. Dapagliflozin Attenuates Na+/H+ Exchanger-1 in Cardiofibroblasts via AMPK Activation. Cardiovasc Drugs Ther  2018; 32(6): 553-8.
[http://dx.doi.org/10.1007/s10557-018-6837-3] [PMID: 30367338] 
[39] 
Miyachi Y, Tsuchiya K, Shiba K, et al. A reduced M1-like/M2-like ratio of macrophages in healthy adipose tissue expansion during SGLT2 inhibition. Sci Rep  2018; 8(1): 16113.
[http://dx.doi.org/10.1038/s41598-018-34305-x] [PMID: 30382157] 
[40] 
Baartscheer A, Schumacher CA, Wüst RC, et al. Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits. Diabetologia  2017; 60(3): 568-73.
[http://dx.doi.org/10.1007/s00125-016-4134-x] [PMID: 27752710] 
[41] 
Liu T, Takimoto E, Dimaano VL, et al. Inhibiting mitochondrial Na+/Ca2+ exchange prevents sudden death in a Guinea pig model of heart failure. Circ Res  2014; 115(1): 44-54.
[http://dx.doi.org/10.1161/CIRCRESAHA.115.303062] [PMID: 24780171] 
[42] 
Uthman L, Baartscheer A, Bleijlevens B, et al. Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation. Diabetologia  2018; 61(3): 722-6.
[http://dx.doi.org/10.1007/s00125-017-4509-7] [PMID: 29197997] 
[43] 
Verma S. Are the Cardiorenal Benefits of SGLT2 Inhibitors Due to Inhibition of the Sympathetic Nervous System? JACC Basic Transl Sci  2020; 5(2): 180-2.
[http://dx.doi.org/10.1016/j.jacbts.2020.01.011] [PMID: 32142070] 
[44] 
Herat LY, Magno AL, Rudnicka C, et al. SGLT2 inhibitor–induced sympathoinhibition: a novel mechanism for cardiorenal protection. JACC Basic Transl Sci  2020; 5(2): 169-79.
[http://dx.doi.org/10.1016/j.jacbts.2019.11.007] [PMID: 32140623] 
[45] 
Liu J, Li L, Li S, et al. Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis. Sci Rep  2017; 7(1): 2824.
[http://dx.doi.org/10.1038/s41598-017-02733-w] [PMID: 28588220] 
[46] 
Patakfalvi L, Brazeau AS, Dasgupta K. Physician experiences with sodium-glucose cotransporter (SGLT2) inhibitors, a new class of medications in type 2 diabetes, and adverse effects. Prim Health Care Res Dev  2018; 23: 1-6.
[PMID: 30032729] 
[47] 
Kim YG, Jeon JY, Han SJ, Kim DJ, Lee KW, Kim HJ. Sodium-glucose co-transporter-2 inhibitors and the risk of ketoacidosis in patients with type 2 diabetes mellitus: A nationwide population-based cohort study. Diabetes Obes Metab  2018; 20(8): 1852-8.
[http://dx.doi.org/10.1111/dom.13297] [PMID: 29569427] 
[48] 
Koufakis T, Mustafa OG, Ajjan RA, et al. The use of sodium-glucose co-transporter 2 inhibitors in the inpatient setting: Is the risk worth taking? J Clin Pharm Ther  2020; 45(5): 883-91.
[http://dx.doi.org/10.1111/jcpt.13107] [PMID: 31905245] 
[49] 
Merovci A, Solis-Herrera C, Daniele G, et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest  2014; 124(2): 509-14.
[http://dx.doi.org/10.1172/JCI70704] [PMID: 24463448] 
[50] 
Goldenberg RM, Berard LD, Cheng AYY, et al.  SGLT2 inhibitor-associated diabetic ketoacidosis: clinical review and recommendations for prevention and diagnosis.  Clin Ther   2016; 38 (2654 ): 2664.
[http://dx.doi.org/10.1016/j.clinthera.2016.11.002] 
[51] 
Garcia-Ropero A, Badimon JJ, Santos-Gallego CG. The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments. Expert Opin Drug Metab Toxicol  2018; 14(12): 1287-302.
[http://dx.doi.org/10.1080/17425255.2018.1551877] [PMID: 30463454] 
[52] 
Cherney DZI, Udell JA. Use of sodium glucose cotransporter 2 inhibitors in the hands of cardiologists: with great power comes great responsibility. Circulation  2016; 134(24): 1915-7.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.116.024764] [PMID: 27956401] 
[53] 
Scheen AJ. Reappraisal of the diuretic effect of empagliflozin in the EMPA-REG OUTCOME trial: Comparison with classic diuretics. Diabetes Metab  2016; 42(4): 224-33.
[http://dx.doi.org/10.1016/j.diabet.2016.05.006] [PMID: 27291329] 
[54] 
Opingari E, Partridge ACR, Verma S, Bajaj HS. SGLT2 inhibitors: practical considerations and recommendations for cardiologists. Curr Opin Cardiol  2018; 33(6): 676-82.
[http://dx.doi.org/10.1097/HCO.0000000000000561] [PMID: 30148719] 
[55] 
Wanner C, Inzucchi SE, Lachin JM, et al. EMPA-REG OUTCOME Investigators. Empagliflozin and progression of kidney disease in type 2 diabetes. Further analysis of the renal outcomes and benefits seen with empagliflozin from the EMPA-REG OUTCOME trial. N Engl J Med  2016; 375(4): 323-34.
[http://dx.doi.org/10.1056/NEJMoa1515920] [PMID: 27299675] 
[56] 
Perkovic V, Jardine MJ, Neal B, et al. CREDENCE Trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med  2019; 380(24): 2295-306.
[http://dx.doi.org/10.1056/NEJMoa1811744] [PMID: 30990260] 
[57] 
Heerspink HJL, Kosiborod M, Inzucchi SE, Cherney DZI. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors. Kidney Int  2018; 94(1): 26-39.
[http://dx.doi.org/10.1016/j.kint.2017.12.027] [PMID: 29735306] 
[58] 
Ruanpeng D, Ungprasert P, Sangtian J, Harindhanavudhi T. Sodium-glucose cotransporter 2 (SGLT2) inhibitors and fracture risk in patients with type 2 diabetes mellitus: A meta-analysis. Diabetes Metab Res Rev  2017; 33(6): e2903.
[http://dx.doi.org/10.1002/dmrr.2903] [PMID: 28440590] 
[59] 
Diabetes Atlas IDF. IDF Diabetes Atlas, 9th ed Brussels, 2019.  Available at: http://www.diabetesatlas.org
[60] 
Davies MJ, D’Alessio DA, Fradkin J, et al. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care  2018; 41(12): 2669-701.
[http://dx.doi.org/10.2337/dci18-0033] [PMID: 30291106] 
[61] 
Verma S, Sharma A, Zinman B, et al. Empagliflozin reduces the risk of mortality and hospitalization for heart failure across Thrombolysis In Myocardial Infarction Risk Score for Heart Failure in Diabetes categories: Post hoc analysis of the EMPA-REG OUTCOME trial. Diabetes Obes Metab  2020; 22(7): 1141-50.
[http://dx.doi.org/10.1111/dom.14015] [PMID: 32227432] 
[62] 
NIH US National Library of Medicine. A Study to Test the Effect of Empagliflozin in Patients Who Are in Hospital for Acute Heart Failure.  Available at: https://clinicaltrials.gov/ct2/show/NCT04049045
[63] 
NIH US National Library of Medicine. Effects of Empagliflozin on Diuresis and Renal Function in Patients With Acute Decompensated Heart Failure (EMPAG-HF).  Available at: https://clinicaltrials.gov/ct2/show/NCT04049045
[64] 
Kubota Y, Yamamoto T, Tara S, et al. Effect of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: rationale. Diabetes Ther  2018; 9(5): 2107-16.
[http://dx.doi.org/10.1007/s13300-018-0480-7] [PMID: 30097993] 

Rights & Permissions Print Cite

Article Metrics

34

2

Journal Information

For Authors

For Editors

For Reviewers

Explore Articles

Open Access

Open Access Articles

For Visitors

DOI https://dx.doi.org/10.2174/1381612826666201103122813	Print ISSN 1381-6128
Publisher Name Bentham Science Publisher	Online ISSN 1873-4286

Current Pharmaceutical Design

Cardio-Protective Effects of Sodium-Glucose Co-Transporter 2 Inhibitors: Focus on Heart Failure

Abstract Play Pause

Related Journals

Related Books

Related Articles

Abstract